<DOC>
	<DOCNO>NCT01196039</DOCNO>
	<brief_summary>This Phase II , double-blind , placebo-controlled , randomize , parallel-group study design evaluate efficacy , safety tolerability MEMP1972A administer patient intravenous ( IV ) infusion treatment allergen-induced asthma .</brief_summary>
	<brief_title>A Study MEMP1972A Prevention Allergen-Induced Airway Obstruction Patients With Mild Asthma ( SOLARIO )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Airway Obstruction</mesh_term>
	<criteria>Mild , stable allergic asthma History episodic wheeze shortness breath FEV1 baseline &gt; = 70 % predict value Males females surgically sterilize , post menopausal past year , use two acceptable method contraception pregnancy least 5 month follow last administration study drug Documented PC20 value prediction start allergen concentration screen Positive skin prick test common standard aeroallergens extract Positive allergeninduced early late airway response A worsening asthma within 6 week precede Visit 1 Acute respiratory infection within 6 week precede Visit 2 ongoing chronic infection History recurrent bacterial infection adult history presence chronic infectious condition Risk exposure , determine investigator , waterborne parasite clinical diagnosis parasitic infection untreated within 3 month prior Visit 5 Lung disease mild allergic asthma History clinically significant hypotensive episode symptom faint , dizziness , lightheadedness History symptom cardiovascular disease History symptoms significant neurologic disease History significant hepatic renal impairment Evidence active suspect cancer history treatment cancer History symptom clinically significant autoimmune disease Any acquire congenital immune deficiency Confirmed positive test HIV hepatitis B C Concomitant disease condition , could interfere conduct study , treatment might interfere conduct study , would , opinion investigator , pose unacceptable risk patient study History serious adverse reaction hypersensitivity drug Clinically significant abnormal chest radiograph within last 12 month Pregnancy lactation positive serum pregnancy test screening Use corticosteroid , immunosuppressive , anticoagulant , medication may interact study drug within 4 week prior Visit 2 Chronic use medication treatment allergic lung disease shortacting Î²2agonists ipratropium bromide Use cromoglycate , nedocromil , leukotriene receptor antagonist , inhibitor 5lipoxygenase permit within 4 week prior Visit 2 Allergen peptide immunotherapy within 6 month prior study treatment Participation investigational drug study within precede 30 day 5 halflives drug , whichever long time Visit 2 Current ( history ) treatment monoclonal antibody chimeric biomolecule within past 5 month , include omalizumab , time Visit 2 Use statin permit within 4 week prior Visit 2 Received live attenuate vaccine within 30 day prior Visit 5 Regular use tobacco product kind within previous 6 month , smoke history &gt; 10 packyears History drug alcohol abuse Donation blood 500 mL within 3 month prior Visit 5 Unwillingness inability comply study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>